Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2013 - 2026)

Amphastar Pharmaceuticals' Non-Current Assets history runs 14 years deep, the most recent figure standing at $378.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 7.11% year-over-year to $378.9 million; the TTM figure through Mar 2026 stood at $378.9 million (up 7.11% YoY), while the FY2025 annual figure was $353.7 million, up 2.64% from the prior year.
• Non-Current Assets was $378.9 million for Q1 2026 at Amphastar Pharmaceuticals, up from $353.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $899.3 million in Q3 2023 to a low of $259.8 million in Q3 2022.
• Historically, Non-Current Assets has averaged $452.3 million across 5 years, with a median of $353.5 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 246.15% in 2023, then sank 63.58% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $264.6 million in 2022, then advanced by 19.3% to $315.6 million in 2023, then rose by 9.18% to $344.6 million in 2024, then increased by 2.64% to $353.7 million in 2025, then rose by 7.12% to $378.9 million in 2026.
• The last three Non-Current Assets figures came in at $378.9 million (Q1 2026), $353.7 million (Q4 2025), and $353.5 million (Q3 2025), per Business Quant data.